Ascendis Pharma A/S's (ASND) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Ascendis Pharma A/S received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook on the stock.
• Despite the sell rating, 15 other analysts have rated the stock as a "Buy," with the average price target set at $244.36.
• The company's stock traded at $210.13 on Wednesday, showing a slight increase in trading volume compared to its average.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. UBS Group reissued a "buy" rating and issued a $307.00 target price (up previously from $306.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Stifel Nicolaus upped their price objective on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Finally, Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $244.36.

Ascendis Pharma A/S Trading Up 0.1%

Shares of Ascendis Pharma A/S stock traded up $0.27 during trading on Wednesday, hitting $210.13. The stock had a trading volume of 560,030 shares, compared to its average volume of 482,178. The firm has a market cap of $12.96 billion, a price-to-earnings ratio of -40.72 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $118.03 and a 12 month high of $214.71. The business's 50-day moving average is $194.63 and its 200 day moving average is $174.75.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently modified their holdings of the business. Compagnie Lombard Odier SCmA bought a new position in Ascendis Pharma A/S in the 2nd quarter worth $39,000. First Horizon Advisors Inc. bought a new position in Ascendis Pharma A/S in the 2nd quarter worth $41,000. Hantz Financial Services Inc. boosted its position in Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 262 shares in the last quarter. Brooklyn Investment Group boosted its position in Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 273 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company's stock valued at $146,000 after acquiring an additional 97 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.